1. Home
  2. GIGM vs TLPH Comparison

GIGM vs TLPH Comparison

Compare GIGM & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GIGM

GigaMedia Limited

SELL

Current Price

$1.51

Market Cap

17.2M

Sector

Technology

ML Signal

SELL

TLPH

Talphera Inc.

HOLD

Current Price

$0.82

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIGM
TLPH
Founded
1998
2005
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
37.9M
IPO Year
2002
2010

Fundamental Metrics

Financial Performance
Metric
GIGM
TLPH
Price
$1.51
$0.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
5.4K
218.9K
Earning Date
05-04-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,151,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.37
$0.38
52 Week High
$1.89
$1.57

Technical Indicators

Market Signals
Indicator
GIGM
TLPH
Relative Strength Index (RSI) 40.91 43.86
Support Level $1.43 $0.76
Resistance Level $1.60 $1.03
Average True Range (ATR) 0.05 0.06
MACD -0.01 -0.00
Stochastic Oscillator 66.67 34.12

Price Performance

Historical Comparison
GIGM
TLPH

About GIGM GigaMedia Limited

GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: